Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) provides injectable drug administration solutions and services for pharmaceutical, biotechnology and generic drug customers. Its business includes elastomer-based packaging components such as stoppers, seals and plungers, nonglass containment technologies, auto-injectors and contract services for device manufacturing, assembly, packaging, validation, analytical testing and regulatory support.
News about West commonly covers quarterly results, revenue guidance, Proprietary Products and Contract Manufacturing performance, capacity additions for high-volume injectable therapies, and demand tied to biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. Other recurring developments include dividends, share repurchase authorizations, investor conference participation and governance or executive-transition updates.
West Pharmaceutical Services (WST) announced a $0.18 per share dividend for Q1 2022, payable on February 2, 2022, to shareholders on record by January 19, 2022. Additionally, the company's Board of Directors approved a share repurchase program for 2022, allowing the buyback of up to 650,000 shares. This program aims to enhance shareholder value and is expected to conclude by December 31, 2022, following the expiration of a previous buyback.
West Pharmaceutical Services (NYSE: WST) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 11:15 a.m. EST. The event will be held virtually, allowing investors to access a live audio webcast in the "Investors" section of the company's website. West is a leader in injectable drug solutions, generating over $2.15 billion in sales during fiscal year 2020. With nearly 10,000 employees across 50 sites, West provides over 40 billion components and devices annually.
West Pharmaceutical Services (NYSE: WST) will participate in the Jefferies London Healthcare Conference from November 16-18, 2021, with a Fireside Chat on November 16, 2021, at 5:40 p.m. GMT. The company will also attend the Stephens Investment Conference in Nashville, TN, from December 1-3, 2021, featuring a Fireside Chat on December 3, 2021, at 11:00 a.m. CST. Webcasts for both events will be available on the company's website, with replays accessible for 90 days. West, a leader in injectable solutions, generated over $2.15 billion in sales in FY 2020.
West Pharmaceutical Services reported a strong Q3 2021, with net sales of $706.5 million, a 28.9% increase year-over-year. Reported diluted EPS rose 112% to $2.31. The company raised its full-year net sales guidance to $2.800-$2.810 billion and adjusted diluted EPS guidance to $8.40-$8.50. A quarterly dividend of $0.18 per share was approved, reflecting a 5.9% increase. Sales growth was driven by proprietary products, particularly from the High-Value Product portfolio.
Summary not available.
West Pharmaceutical Services announced the launch of its DeltaCube™ Modeling Platform and NovaGuard® SA Pro Safety System for 0.5mL Standard Glass Syringes at Interphex from October 19-21 in New York. The DeltaCube™ platform aids in vial integrity modeling, enhancing decision-making in container closure systems. The NovaGuard® SA Pro system expands product offerings for pre-filled syringes, addressing safety with innovative features to protect against needlestick injuries. This initiative reflects a strategic response to market demands for safer and more efficient drug delivery solutions.
West Pharmaceutical Services (NYSE: WST) will announce third-quarter 2021 financial results on October 28, 2021, before market opening. A conference call will take place at 9:00 a.m. Eastern Time to discuss the results and future business outlook. Interested participants can join by calling 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 5587559. The event will be streamed live on the company's website, with an archived version available afterward until November 4, 2021.
West Pharmaceutical Services (NYSE: WST) has appointed Molly Joseph to its Board of Directors, expanding the board to 11 members. Joseph, 47, previously served as CEO of UnitedHealthcare Group for over a decade, where she led the development of a significant global health business. Her experience includes oversight of extensive medical facilities and strategic corporate development. With her extensive healthcare and board experience, the company anticipates that her expertise will enhance its mission in delivering healthcare solutions worldwide.
West Pharmaceutical Services reported a strong second quarter in 2021, with net sales of $723.6 million, a growth of 37.3%. Organic sales growth was 30.6%, and diluted EPS rose to $2.47, marking a 104% increase. The company raised its full-year 2021 net sales guidance to $2.760-$2.785 billion and adjusted-diluted EPS guidance to $8.05-$8.20. The growth was driven by demand for high-value product components, particularly related to COVID-19 vaccines. Operating cash flow reached $233.1 million, reflecting a 13.6% increase.
West Pharmaceutical Services (NYSE: WST) will announce its second-quarter 2021 financial results on July 29, 2021, prior to market opening. Following this, a conference call is scheduled for 9:00 a.m. Eastern Time featuring a discussion on results and business outlook. Interested participants can join the call by dialing 877-930-8295 (U.S.) or 253-336-8738 (International) with conference ID 3089097. An online archive will be accessible on the company’s website for future reference.